Heparin harmonization on the horizon?
This article was originally published in The Gold Sheet
Executive Summary
Both the United States Pharmacopeia and the European Pharmacopoeia Commission have announced that their respective pharmacopoeias have adopted revised monographs for heparin calcium and heparin sodium that are more closely aligned with each other. The Japanese Pharmacopoeia is currently reviewing a draft revision for heparin sodium. These announcements follow the recent serious problems with heparin, including 81 deaths, and the emergency measures to react to the safety issues involved
You may also be interested in...
U.S. Pharmacopeia Ramps Up Drug Quality, Safety Cooperation Across Asia With Four New Agreements With China, ASEAN States
BEIJING - In moves that could ultimately help elevate safety and quality standards for drugs produced across Asia, including those exported to North America, the United States Pharmacopeial Convention has signed a series of agreements with China and the Association of Southeast Asian Nations on closer scientific exchanges and joint testing of pharmaceuticals
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.
Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation
As Eli Lilly chief information and digital officer Rau speaks of generative AI models training humans on drug discovery, Bristol Myers Squibb CDTO Meyers of wearables aiding cell therapy and Microsoft Research India MD Rajamani of interoperability no longer being a huge challenge, a discussion at the BioAsia summit highlights a fundamental shift in R&D approaches.